Table 4.
ST6GAL1methylation b | ||||||
---|---|---|---|---|---|---|
n a | negative | positive | P-value c | Spearmanrs | ||
Parameter: | ||||||
Age at diagnosis | ||||||
≤69 years | 29 | 19 | 10 | 0.858 | -0.24 | |
>69 years | 31 | 21 | 10 | |||
Gender | ||||||
Female | 9 | 6 | 3 | 1.000 | <0.001 | |
Male | 51 | 34 | 17 | |||
Tumor subtype | ||||||
Non-invasive | 16 | 12 | 4 | 0.343 | 0.167 | |
Invasive | 31 | 18 | 13 | |||
Histological tumor graded | ||||||
Low grade | 14 | 11 | 3 | 0.347 | 0.139 | |
High grade | 46 | 29 | 17 | |||
Tumor staged | ||||||
pTa-pT1 | 19 | 15 | 4 | 0.073 | 0.276 | |
pT2-pT4 | 27 | 14 | 13 | |||
ST6GAL1 mRNA expressione | ||||||
Low | 18 | 9 | 9 | 0.022 | -0.355 | |
High | 30 | 25 | 5 |
aOnly patients with primary bladder cancer were included; bbased on MSP; cFisher’s exact test; daccording to WHO 2004 classification; ecut-off: 0.5 in relation to NU expression; significant p-values are marked in bold face.